Featured Research

from universities, journals, and other organizations

One step closer to Parkinson's drug

Date:
June 27, 2012
Source:
Van Andel Research Institute
Summary:
A new study details how Parkinson's disease spreads through the brain. Experiments in rat models uncover a process previously used to explain mad cow disease, in which misfolded proteins travel from sick to healthy cells. This model has never before been identified so clearly in a living organism, and the breakthrough brings researchers one step closer to a disease-modifying drug for Parkinson's.

Van Andel Institute announces that researchers at Lund University in Sweden have published a study detailing how Parkinson's disease spreads through the brain. Experiments in rat models uncover a process previously used to explain mad cow disease, in which misfolded proteins travel from sick to healthy cells. This model has never before been identified so clearly in a living organism, and the breakthrough brings researchers one step closer to a disease-modifying drug for Parkinson's.

"Parkinson's is the second most common neurodegenerative disorder after Alzheimer's disease," said Patrik Brundin M.D., Ph.D., Jay Van Andel Endowed Chair in Parkinson's Research at Van Andel Research Institute (VARI), Head of the Neuronal Survival Unit at Lund University and senior author of the study. "A major unmet medical need is a therapy that slows disease progression. We aim to better understand how Parkinson's pathology progresses and thereby uncover novel molecular targets for disease-modifying treatments."

Previous research demonstrates that a misfolded protein known as alpha-synuclein protein gradually appears in healthy young neurons transplanted to the brains of Parkinson's patients. This discovery gave rise to the group's hypothesis of cell-to-cell protein transfer, which has since been demonstrated in laboratory experiments.

In the current study, published this week in the Public Library of Science (PLoS) One, researchers for the first time were able to follow events in the recipient cell as it accepts the diseased protein by allowing it to pass its outer cell membrane. The experiments also show how the transferred proteins attract proteins in the host cell leading to abnormal folding or "clumping" inside the cells. "This is a cellular process likely to lead to the disease process as Parkinson's progresses, and it spreads to an increasing number of brain regions as the patient gets sicker," said Elodie Angot, Ph.D., of Lund University's Neuronal Survival Unit, and lead co-author of the study.

"In our experiments, we show a core of unhealthy human alpha-synuclein protein surrounded by alpha-synuclein produced by the rat itself. This indicates that this misfolded protein not only moves between cells but also acts as a "seed" attracting proteins produced by the rat's brain cells," said Jennifer Steiner, Ph.D., of Lund University and Van Andel Institute's Center for Neurodegenerative Science, the study's other lead author.

These findings are consistent with results from previous laboratory cell models and for the first time extend this observation into a living organism. However, it remains unclear exactly how alpha-synuclein gains access from the extracellular space to the cytoplasm of cells to act as a template for naturally occurring alpha-synuclein, causing the naturally-occurring protein to, in turn, misfold. Further studies are needed to clarify this important step in the process.

The discovery does not reveal the root of Parkinson's disease, but in conjunction with disease models developed by Lund University researchers and others, could enable scientists to develop new drug targets aimed at mitigating or slowing the effects of the disease, which currently strikes more than 1% of people over the age of 65.


Story Source:

The above story is based on materials provided by Van Andel Research Institute. Note: Materials may be edited for content and length.


Journal Reference:

  1. Elodie Angot, Jennifer A. Steiner, Carla M. Lema Tom้, Peter Ekstr๖m, Bengt Mattsson, Anders Bj๖rklund, Patrik Brundin. Alpha-Synuclein Cell-to-Cell Transfer and Seeding in Grafted Dopaminergic Neurons In Vivo. PLoS ONE, 2012; 7 (6): e39465 DOI: 10.1371/journal.pone.0039465

Cite This Page:

Van Andel Research Institute. "One step closer to Parkinson's drug." ScienceDaily. ScienceDaily, 27 June 2012. <www.sciencedaily.com/releases/2012/06/120627103348.htm>.
Van Andel Research Institute. (2012, June 27). One step closer to Parkinson's drug. ScienceDaily. Retrieved October 1, 2014 from www.sciencedaily.com/releases/2012/06/120627103348.htm
Van Andel Research Institute. "One step closer to Parkinson's drug." ScienceDaily. www.sciencedaily.com/releases/2012/06/120627103348.htm (accessed October 1, 2014).

Share This



More Health & Medicine News

Wednesday, October 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Newsy (Sep. 30, 2014) — The CDC says a new case of Ebola has not been reported in Nigeria for more than 21 days, leading to hopes the outbreak might be nearing its end. Video provided by Newsy
Powered by NewsLook.com
UN Ebola Mission Head: Immediate Action Is Crucial

UN Ebola Mission Head: Immediate Action Is Crucial

AFP (Sep. 30, 2014) — The newly appointed head of the United Nations Mission for Ebola Emergency Response (UNMEER), Anthony Banbury, outlines operations to tackle the virus. Duration: 00:39 Video provided by AFP
Powered by NewsLook.com
CDC Confirms First Case of Ebola in US

CDC Confirms First Case of Ebola in US

AP (Sep. 30, 2014) — The CDC has confirmed the first diagnosed case of Ebola in the United States. The patient is being treated at a Dallas hospital after traveling earlier this month from Liberia. (Sept. 30) Video provided by AP
Powered by NewsLook.com
New Breast Cancer Drug Extends Lives In Clinical Trial

New Breast Cancer Drug Extends Lives In Clinical Trial

Newsy (Sep. 30, 2014) — In a clinical trial, breast cancer patients lived an average of 15 months longer when they received new drug Perjeta along with Herceptin. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins